EFFECT OF METHOTREXATE THERAPY ON PARAOXONASES-1ACTIVITY & SERUM IL-10 LEVELS IN EGYPTIAN PATIENTS WITH RHEUMATOID ARTHRITIS Shereen Rashad kaddafy1 and Abdelaziz A. Mustafa
1Departments of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University
2Department of rheumatology, physical medicine and rehabilitation, Faculty of Medicine, Al Azhar University
Background: Methotrexate (MTX) the “anchor drug” and the first choice for treatment of Rheumatoid Arthritis is able to generate reactive oxygen species (ROS). The present study aims to investigate the effect MTX treatments on il-10 and antioxidant status of the patients with rheumatoid arthritis. Subjects and methods: The present study included 80 Egyptian subjects divided into 3 groups: group I; early diagnosed rheumatoid arthritis patients who did not receive medications yet (n=30 patients), group II; rheumatoid arthritis patients who received MTX for at least 6 months (n=30 subjects) and group III; healthy control group (n=20 subjects). Serum il-10 and serum paraoxonase enzyme (PON-1) levels were measured. Results: There was no statistically significant alteration in serum levels of il-10 or PON-1 after the MTX therapy. The levels of il-10 were higher in both groups than controls. The levels of paroxonase-1 were lower in both groups than controls with no significant difference between both patients groups. Conclusions: no statistically significant difference was found in the levels of PON-1 in patients who received MTX therapy and those who did not receive MTX. First of the possible cause for this might be the nature of disease itself as RA is one of the conditions that induce oxidative stress with no effect of MTX on oxidation or may be the expected increase of OS is compensated to some extend by reduction of inflammation obtained by MTX.